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P R E V I E W SUnlikely partners in weight loss?
The classic role of bile acids is as a key component of cholesterol homeostasis. New evidence recently published in
Nature (Watanabe et al., 2006), however, describes a bile acid signaling pathway that controls energy expenditure through
induction of thyroid hormone signaling pathways. This work may point to new approaches to tissue-specific metabolic
regulation.Maintenance of normal serum choles-
terol levels is essential for life. Excess
cholesterol is eliminated by hepatic con-
version to soluble bile acids (BAs), which
are excreted into the small intestine.
Most of the BA pool, however, is subse-
quently reabsorbedand recycled through
the enterohepatic circulation. The pro-
duction of BAs from cholesterol is regu-
lated by the farnesoid X receptor (FXR),
which when bound by BAs ultimately
reduces expression of cholesterol 7 a-
hydroxylase, the rate-limiting enzyme in
BA synthesis (for review, see Kalaany
and Mangelsdorf [2005]).
In addition to acting through this clas-
sic nuclear hormone signaling pathway,
BAs have also been shown to signal in
an FXR-independent manner by binding
to a novel G protein-coupled cell-surface
receptor, termed TGR5 (Maruyama et al.,
2002). Activation of TGR5 leads to in-
creased intracellular cAMP production,
which modifies macrophage function
(Kawamata et al., 2003). Now a landmark
paper recently published in Nature by
Watanabe et al. (2006) describes an
FXR-independent role for BAs in control-
ling energy expenditure (EE). The authors
demonstrate that BAs increase EE in
brown adipose tissue of mice, resulting
in prevention of diet-induced obesity
and insulin resistance. Based on in vitro
studies in human skeletal myocytes,
they postulate that bile acids would also
increase EE in man.
The novel role for BAs in regulating cel-
lular metabolism as described by Wata-
nabe et al. (2006) is illustrated in Figure 1.
BAs bind to the TGR5 receptor (coupled
to Gs), which leads to increased intracel-
lular cAMP production and induction of
the Dio2 gene whose gene product isCELL METABOLISM : FEBRUARY 2006type 2 iodothyronine deiodinase or D2.
Several major BAs such as cholic acid,
deoxycholic acid, and chenodeoxycholic
acid activate this pathway, but a syn-
thetic FXR agonist, GW4064, has no ef-
fect. BAs induce D2 expression in ther-
mogenically important tissues such as
murine brown fat and human skeletal my-
ocytes, because only these tissues ex-
press both TGR5 and D2. D2 then con-
verts locally available T4 to T3, without
leading to an increase in circulating thy-
roid hormone levels, resulting in an in-
crease in oxygen consumption and EE.
In addition to D2, several genes involved
in EE were increased in brown adipose
tissue after BA treatment: peroxisome
proliferator-activated receptor g coacti-
vator-1a and -1b, uncoupling protein
(UCP) 1 and 3, straight chain acyl-CoA
oxidase 1, and muscle carnitine palmi-
toyltransferase. The increase in D2 ex-
pression, however, is essential for the in-
crease in EE by BAs, since diet-induced
obesity is prevented in wild-type but not
D2 knockout mice after BA treatment.
A high-fat diet also increases D2 ex-
pression in brown adipose tissue, but
this effect appears to be downstream
from TGR5 (see Figure 1), since cAMP
levels are not increased to the same ex-
tent as D2 levels by this diet. BAs in-
crease cAMP and D2 levels in brown ad-
ipose tissue, but these effects are much
more pronounced in tissue obtained
from mice fed a high-fat diet rather than
fed a regular diet. The authors point out
that this might explain why BAs prevent
diet-induced obesity but do not affect
the bodyweight of animals fed a regular
diet. Thus, the BA effect is specific to
thermogenic tissues and is observed
only when mice are fed a high-fat diet.Exactly how T3, produced locally by
D2, mediates an increase in oxygen con-
sumption and EE in murine brown adi-
pose tissue or human skeletal muscle re-
mains to be clarified. One potential
mechanism is T3-mediated induction of
UCP expression. UCPs dissipate the
proton gradient generated by the elec-
tron transport chain as heat resulting in
a reduction in ATP synthesis. Since
both T3 and cAMP are known to increase
expression of UCP1 in brown adipose
tissue (Ribeiro et al., 2001), this could
potentially explain the increase in EE ob-
served in mice treated with BAs. In con-
trast, fat-free body mass, which is pre-
dominantly skeletal muscle, is the major
determinant of basal metabolism in
humans, which lack significant amounts
of brown adipose tissue (except in the
neonatal period; Ravussin et al., 1986).
Importantly, skeletal muscle UCP3 ex-
pression is positively correlated with EE
in the Pima Indians, increased by T3,
and decreased in type 2 diabetics (for
review, see Hesselink and Schrauwen
[2005]). Thus like UCP1, UCP3 induction
in skeletal muscle might mediate an in-
crease in EE in humans after BA treat-
ment promoting weight loss and insulin
sensitivity.
The mechanism(s) by which BAs in-
crease EE, however, is likely to be more
complex than noted above. For example,
in the 1930s, patients given the artificial
uncoupler of oxidative phosphorylation,
2,4 dinitrophenol (DNP), at low to mod-
erate doses demonstrated significant
weight loss without associated increases
in urinary nitrogen excretion or heart rate
(for review, see Harper et al. [2001]).
Higher doses of DNP, in contrast, were
associated with cataract formation and81
P R E V I E W SFigure 1. Role of bile acids in metabolism
An FXR-independent mechanism for BA action is shown. These pathways are active in thermogenically impor-
tant tissues such a murine brown adipose tissue and human skeletal muscle due to coexpression of TGR5 and
D2. TGR5 signaling generates intracellular cAMP, via Gs activation of adenyl cyclase (AC), which subsequently
activates Dio2 gene expression through a classic cAMP response element (CRE). It is also possible that the
TGR5 signaling pathway could also directly activate expression of certain EE gene products. The precise
mechanism whereby locally generated T3 activates oxygen consumption and EE in these tissues is unclear
but could involve direct activation of EE genes by binding to thyroid hormone receptors found on thyroid hor-
mone response elements (TREs). Dio2 gene expression is activated by a high-fat diet distal to cAMP gener-
ation, although the exact location of the effect is unknown.unexplained deaths, which led to its with-
drawal from the market. Thyroid hor-
mone treatment for weight loss has also
been tried for decades. Unlike DNP,
though, thyroid hormone treatment in-
creased both urinary nitrogen excretion
and heart rate; the former is thought to
explain the muscle weakness found in
states of thyroid hormone excess. Thus,
thyroid hormone actions overlap with,
but are not identical to, those observed
with mitochondrial uncouplers and in-
clude the possibility of muscle wasting.
Moreover, while local T3 generation is
clearly necessary for the EE response, it
may not be sufficient. For example, T3
could act by binding to nuclear T3 recep-
tors to directly or indirectly increase
genes involved in EE, but this effect
may also require activation of the cAMP
signaling pathway, as suggested from82studies in brown adipose tissue (for re-
view, see Bianco et al. [2002]). Finally, in
addition to inducing expression of D2
and UCPs, BAs also increase expression
of genes involved in fatty acid metabo-
lism as well as those that control expres-
sion ofmetabolic genes by functioning as
transcriptional coactivators.
Given what we now know about this
novel action of BAs, could they be used
as a weight loss drug in humans? If it
can be proven in clinical studies that
skeletal muscle is the only significant
metabolic target of BAs inman, then their
use may provide a way to boost EE in
muscle without increasing overall thyroid
hormone action. One would need to be
certain, though, that fat, not protein,
was the fuel used by muscle to meet
the increase in EE. The overall safety of
BAs would also need to be established,as they are potentially hepatotoxic. Fur-
thermore, it is unclear what effect BAs
would have in tissues that express
TGR5 but not D2, such as the heart,
lung, kidney, liver, and spleen. Regard-
less, this new and exciting connection
between BAs and T3, two unlikely part-
ners in weight loss, opens a new chapter
in metabolic regulation of body weight.
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